In contrast to effects of CCN2 Ab treatment observed on some inflammatory marker mRNA levels in liver, by H&E staining, no effect of the CCN2 Ab treatment on hepatic steatosis compared with control IgG treatment was observed in any mouse group examined (neither HFD, nor in HFD+DM, data not shown). This evidence concerns the gene CCN2 and Hepatic steatosis.